UNSPSC 51162353: Ibuprofen/pseudoephedrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER.

UNSPSC 51162353 Ibuprofen/pseudoephedrine is a Commodity code that covers over-the-counter pharmaceutical products, though recent state and local procurement activity under this code shows a broader scope encompassing generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers and direct-purchase arrangements. State and local buyers soliciting under this code include county health departments and state cooperative purchasing alliances administering multi-jurisdictional pharmaceutical supply contracts. Seminole County, Florida has posted competitive bids for naloxone and drug deactivation systems through direct procurement, while the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, has issued an RFP to establish statewide and multi-state contracts for generic pharmaceuticals and OTC products distributed to participating state and local government facilities across multiple jurisdictions including Oregon.

Recent activity concentrates in Florida and Minnesota with multi-state reach through cooperative purchasing mechanisms. Seminole County's IFB60459723LAS (due July 26, 2023) seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, with contracts structured for two-year initial terms and optional one-year renewals. MMCAP's RFP S1070000015802 (due March 26, 2026) establishes multiple contracts for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with awarded vendors effective July 1, 2026 and products required in the marketplace by May 15, 2026. The MMCAP procurement weights price competitiveness at 75 percent and requires vendors to maintain compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, with comprehensive commercial general liability insurance of $5 million per occurrence and network security and privacy liability of $2 million.